{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:27Z","timestamp":1740107427650,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T00:00:00Z","timestamp":1525046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00393-018-0471-0","type":"journal-article","created":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T07:19:40Z","timestamp":1525072780000},"page":"183-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of adult idiopathic inflammatory myopathies with conventional immunosuppressive drugs","Behandlung von idiopathischen entz\u00fcndlichen Muskelerkrankungen des Erwachsenen mit konventionellen Immunsuppressiva"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-286X","authenticated-orcid":false,"given":"G.","family":"Key\u00dfer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Zierz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kornhuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,30]]},"reference":[{"key":"471_CR1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/art.30156","volume":"63","author":"AL Mammen","year":"2011","unstructured":"Mammen AL, Chung T, Christopher-Stine L et al (2011) Autoantibodies against 3\u2011hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63:713\u2013721. \n                    https:\/\/doi.org\/10.1002\/art.30156","journal-title":"Arthritis Rheum"},{"key":"471_CR2","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1136\/annrheumdis-2013-205127","volume":"74","author":"C Dobloug","year":"2015","unstructured":"Dobloug C, Garen T, Bitter H et\u00a0al (2015) Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a\u00a0large and unselected Norwegian cohort. Ann Rheum Dis 74:1551\u20131556. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-205127","journal-title":"Ann Rheum Dis"},{"key":"471_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","volume":"387","author":"N Ruperto","year":"2016","unstructured":"Ruperto N, Pistorio A, Oliveira S et al (2016) Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a\u00a0randomised trial. Lancet 387:671\u2013678. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)01021-1","journal-title":"Lancet"},{"key":"471_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/joim.12511","volume":"280","author":"CV Oddis","year":"2016","unstructured":"Oddis CV (2016) Update on the pharmacological treatment of adult myositis. J\u00a0Intern Med 280:63\u201374. \n                    https:\/\/doi.org\/10.1111\/joim.12511","journal-title":"J Intern Med"},{"key":"471_CR5","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1586\/1744666X.2015.1082908","volume":"11","author":"S Moghadam-Kia","year":"2015","unstructured":"Moghadam-Kia S, Aggarwal R, Oddis CV (2015) Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Rev Clin Immunol 11:1265\u20131275. \n                    https:\/\/doi.org\/10.1586\/1744666X.2015.1082908","journal-title":"Expert Rev Clin Immunol"},{"key":"471_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/nejm197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N\u00a0Engl J Med 292:344\u2013347. \n                    https:\/\/doi.org\/10.1056\/nejm197502132920706","journal-title":"N Engl J Med"},{"key":"471_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00124743-199504000-00007","volume":"1","author":"ED Newman","year":"1995","unstructured":"Newman ED, Scott DW (1995) The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J\u00a0Clin Rheumatol 1:99\u2013102","journal-title":"J Clin Rheumatol"},{"key":"471_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","volume":"92","author":"TW Bunch","year":"1980","unstructured":"Bunch TW, Worthington JW, Combs JJ et\u00a0al (1980) Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 92:365\u2013369","journal-title":"Ann Intern Med"},{"key":"471_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/art.1780240107","volume":"24","author":"TW Bunch","year":"1981","unstructured":"Bunch TW (1981) Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 24:45\u201348","journal-title":"Arthritis Rheum"},{"key":"471_CR10","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1164\/ajrccm.164.7.2103110","volume":"164","author":"WW Douglas","year":"2001","unstructured":"Douglas WW, Tazelaar HD, Hartman TE et al (2001) Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164:1182\u20131185. \n                    https:\/\/doi.org\/10.1164\/ajrccm.164.7.2103110","journal-title":"Am J Respir Crit Care Med"},{"key":"471_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","volume":"84","author":"Y Troyanov","year":"2005","unstructured":"Troyanov Y, Targoff IN, Tremblay JL et\u00a0al (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84:231\u2013249","journal-title":"Medicine (Baltimore)"},{"key":"471_CR12","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/rheumatology\/keu442","volume":"54","author":"F Ibrahim","year":"2015","unstructured":"Ibrahim F, Choy E, Gordon P et al (2015) Second-line agents in myositis: 1\u2011year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rheumatology 54:1050\u20131055. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/keu442","journal-title":"Rheumatology"},{"key":"471_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/030097400750001897","volume":"29","author":"J Vencovsky","year":"2000","unstructured":"Vencovsky J, Jarosova K, Machacek S et\u00a0al (2000) Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29:95\u2013102","journal-title":"Scand J Rheumatol"},{"issue":"Suppl 01","key":"471_CR14","first-page":"S53","volume":"199","author":"JW Miller","year":"2002","unstructured":"Miller JW, Walsh Y et\u00a0al (2002) Randomized double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J\u00a0Neurol Sci 199(Suppl 01):S53","journal-title":"J Neurol Sci"},{"key":"471_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","volume":"94","author":"MM Joffe","year":"1993","unstructured":"Joffe MM, Love LA, Leff RL et\u00a0al (1993) Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a\u00a0comparison of their efficacy. Am J Med 94:379\u2013387","journal-title":"Am J Med"},{"key":"471_CR16","unstructured":"Vencovsky J, Institute of Rheumatology Prague (2016) Combined Treatment of Methotrexate\u00a0+ Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM (Prometheus). \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00651040\n                    \n                   (last update posted: May 12, 2016)"},{"issue":"Suppl 11","key":"471_CR17","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1002\/acr.20532","volume":"63","author":"LG Rider","year":"2011","unstructured":"Rider LG, Werth VP, Huber AM et al (2011) Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res 63(Suppl 11):S118\u2013S157. \n                    https:\/\/doi.org\/10.1002\/acr.20532","journal-title":"Arthritis Care Res"},{"key":"471_CR18","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","volume":"15","author":"L Musset","year":"2016","unstructured":"Musset L, Allenbach Y, Benveniste O et al (2016) Anti-HMGCR antibodies as a\u00a0biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a\u00a0large international multi-center study. Autoimmun Rev 15:983\u2013993. \n                    https:\/\/doi.org\/10.1016\/j.autrev.2016.07.023","journal-title":"Autoimmun Rev"},{"key":"471_CR19","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a\u00a0randomized, placebo-phase trial. Arthritis Rheum 65:314\u2013324. \n                    https:\/\/doi.org\/10.1002\/art.37754","journal-title":"Arthritis Rheum"},{"key":"471_CR20","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","volume":"54","author":"H Andersson","year":"2015","unstructured":"Andersson H, Sem M, Lund MB et al (2015) Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology 54:1420\u20131428. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kev004","journal-title":"Rheumatology"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0471-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-018-0471-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0471-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T09:06:23Z","timestamp":1556615183000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-018-0471-0"}},"subtitle":["Results of a\u00a0retrospective study","Ergebnisse einer retrospektiven Studie"],"short-title":[],"issued":{"date-parts":[[2018,4,30]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["471"],"URL":"https:\/\/doi.org\/10.1007\/s00393-018-0471-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2018,4,30]]},"assertion":[{"value":"30 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"G.\u00a0Key\u00dfer, S.\u00a0Zierz, and M.\u00a0Kornhuber declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}